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replicon cells. Apoptosis resistance was showed in CD44
knockdown HCV replicon and HCV-infected cells treated by
ActD.
Conclusion: These results suggested that there had an
intentive relationship between CD44, especially CD44v6
expression and anti-apoptosis in liver cancer tissues.
PP-139 Cutaneous necrosis after injection of interferon
alfa-2b in a patient with HCV-related
decompensated cirrhosis
Z.X. Li1, F.P. Ji2, Z.H. Peng1, H. Deng2. 1Department
of Dermatology and Venereology, the Second Afﬁliated
Hospital, College of Medicine, Xi’an Jiaotong University,
Xi’an, China, 2Department of Infectious Disease, the
Second Afﬁliated Hospital, College of Medicine, Xi’an
Jiaotong University, Xi’an, China
Introduction: Cutaneous necrosis as a result of interferon
alfa is an infrequent complication with unknown
pathogenesis. We report a patient who developed local
cutaneous reactions at sites of injection after the
administration of interferon alfa-2b.
Case description: A 55-year-old woman with HCV-related
decompensated cirrhosis treated with every other day
subcutaneous injections of interferon alfa-2b (210MU) in
combination with ribavirin (800mg/d). Six months later,
a painful, erythematous, indurated plaque with centrally
ulcerated about 1.2 cm in diameter initially developed
on right abdomen. One week later, an additional ulcer
measuring 2 cm in maximum diameter, with peripheral
erythema and purulent contents, developed at the other
injection site on the left abdomen (Fig. 1). Results of skin
cultures were negative. A skin biopsy specimen showed
the presence of ulceration with ﬁbroplasia and vascular
proliferation consistent with a re-epithelializing ulceration.
The patient was advised to avoid injection on abdomen and
to intramuscular injection at triangular muscle with same
dose. The ulcers were treated with Mupirocin ointment,
healed in 1 months, and did not recur. Our case suggests
that the cutaneous lesions maybe healed without requiring
interruption or dose modiﬁcation of interferon after local
care and change of injection site.
Figure 1.
PP-140 Difference in liver function tests in patients
with chronic HCV-infection depend on some
predisposing factors
N. Sargsyants1 *. 1Armenicum Clinical Center, Armenia
Background: Aim of the study was comparison of liver
function tests, including ferritin, in patients with chronic
HCV-infection depends on patients age, gender, body mass
index (BMI), disease limitation, presence of anti bodies to
HBV, alcohol and drug abuse.
Methods: Evaluation of albumin, billirubin, ALT, AST, and
GGT was performed in 50 patients with chronic HCV-
infection by biochemical analyzer HumaStar 300. For
measurement of plasma ferritin level we used two-site
immunoenzymatic (“sandwich”) assay. Statistic analyses
were carried out with SPSS 11.0 and Excel.
Result: Level of AST was signiﬁcantly higher in HCV-infected
patients with obesity (BMI less than 25 56.8±8.0; BMI
25 30 59.3±11.9; BMI more than 30 79.4±20.1). GGT
was signiﬁcantly higher in HCV-infection with duration of
disease more than 10 years (less than 5 years 77.0±25.7;
5 10 years 88.7±9.7; more than 10 159.2±33.6).
Ferritinemia was higher in male in comparison with female
(326±38.4 vs. 108.2±44.7) and in long history of HCV-
infection (up to 5 years 198.8±45.9; 5 10 years
251.1±39.1; more than 10 546.5±80.8).
Conclusion: Signiﬁcant difference revealed in some liver
enzymes and ferritin depends on HCV-infected patients’
gender, BMI and limitation of disease.
Table 1. Liver function tests in patients with chronic HCV-infection
(n = 50)
Parameter Normal
range
Unit m SD SE Median Min Max 95% CI
Albumin 38 51 g/l 46.7 4.98 0.75 47 35 57.9 45.2 48.2
Bilirubin total <18.8 mmol/l 12.55 7.21 1.02 10.7 3.7 39.5 10.6 14.6
Bilirubin direct <4.3 mmol/l 3.09 2.36 0.33 2.4 0.6 12 2.44 3.75
AST <37 U/l 60.98 46.7 6.61 48 14 250 48.0 73.9
ALT <42 U/l 103.22 63.38 8.96 93 13 330 85.7 120.8
GGT 11 61 U/l 91.19 73.11 10.6 69.5 16 350 70.5 111.9
Ferritin 23.9 336.2 ng/dl 236.8 71.25 32.6 197.9 4.7 829.1 173.2 300.4
Table 2. Liver function tests in patients with chronic HCV-infection
depend on gender, age, disease limitation, BMI, HBV past-infection,
alcohol and drugs abuse
Criteria n Albumin Bilirubin ALT AST GGT Ferritin
Gender
Male
Female
42
8
46.6±0.7
45.9±1.6
12.8±1.2
12.0±1.4
110.6±9.8
75.5±24.2
65.2±8.0
54.5±14.1
104.7±12.0
59.5±26.5
326.0±38.4*
108.2±44.7
Age
<30
<31 40
41 50
>50
13
18
16
3
48.0±1.4
45.1±0.9
47.1±1.7
43.0±4.2
12.5±2.4
12.8±1.5
12.1±2.0
13.3±2.0
92.2±14.8
115.9±18.3
96.7±12.9
109.3±49.0
45.6±8.0
75.6±15.4*
53.8±7.0
78.0±26.6
76.7±14.1
96.8±20.1
99.6±20.9
71.0±8.0
157.3±32.1
357.4±50.9
293.7±90.7
90.6±18.6
BMI
<25
25 30
>30
21
21
8
47.1±1.2
45.7±1.2
48.1±1.8
14.4±2.0
10.4±1.0
13.5±2.0
106.0±15.9
90.0±13.3
117.9±15.5
56.8±8.0
59.3±11.9
79.4±20.1*
84.0±17.8
92.4±16.7
151.5±24.3
232.7±14.5
335.9±63.3
300.6±73.9
Disease limitation, years
<5
5 10
>10
13
26
10
48.2±1.4
45.4±0.7
47.6±2.2
13.0±2.6
12.8±1.5
12.4±0.7
78.2±11.2
113.6±14.0
126.8±19.7
41.3±7.2
70.4±11.0
77.5±16.6
77.0±25.7
88.7±9.7
159.2±33.6*
198.8±45.9
251.1±39.1
546.5±80.8*
HBcAb
Yes
No
16
32
46.5±1.3
46.1±0.8
9.6±0.9
14.4±1.5*
94.3±11.5
113.3±12.8
56.1±10.2
68.1±9.8
86.7±13.2
100.6±15.5
249.4±49.2
313.3±49.3
IVDU
Yes
No
23
26
46.1±0.9
46.7±1.0
12.3±1.8
13.2±1.2
109.4±13.6
104.6±12.6
54.9±7.2
72.3±11.9
85.3±11.0
110.1±18.5
326.2±47.6
262.2±52.2
Alcohol abuse
Ectb
HeT
17
32
45.0±1.0
47.2±0.9
10.4±1.1
14.1±1.5
107.7±11.6
106.4±12.7
57.0±7.3
67.9±10.3
107.2±16.4
94.1±15.1
340.2±71.7
264.8±40.5
Values are mean±SE.
*p-value <0.05.
PP-141 Study of the serodynamics and viral clearance
with Reiferon Retard® in chronic Hepatitis C
patients in Egypt
M.A. Hamid1,2 *. 1VHRL Egypt, 2Menia University, Egypt
Objective: Study Serodynamics and viral clearance with
Reiferon Retard® in naïve Egyptian HCV patients mostly
genotype 4.
Methodology: 28 HCV patients randomly selected from
78 patients treated with Reiferon Retard®. 14 showed
sustained viral response and 14 were non responders and
relapsers. Assessment of serodynamics, viral load, viral
clearance and genotyping were performed on blood samples
collected at time of recruitment and at weeks 8, 12 and
Poster Presentations, Poster Session Hepatitis C S85
24. Standard curves for blood Interferon concentration were
generated for given doses. Interferon levels were measured
daily for 7 days in all patients using ELISA assay speciﬁc to
used Interferon molecule.
Results: All samples were reactive with ELISA assay.
Concentration and assay results correlated in a linearly
manner. Standard curve was generated for each run of
samples for all patients. Interferon level has been traced
from 1st to 7th day.
There was signiﬁcant inter-patient variation in levels
of detectable interferon for both responders and non-
responders. In all 7 cases with sustained viral response,
interferon levels were low or undetectable in days 6 and
7. Even one patient whose interferon level was traced in
the 4th day was also a responder. There is no signiﬁcant
difference between responders and non-responders either
in daily median concentration through-out the 7 days, nor
in the association of viral load or genotype to interferon
concentration with viral clearance.
Conclusion: Tracing of single dose Reiferon Retard®
demonstrated detectable interferon levels up to 7 days.
Although interferon levels were low or undetectable in 7
out of 14 cases at days 6 and 7, sustained viral response
was achieved in all cases. Suggested explanation: interferon
attaches to cell receptors by PEG molecule and acts on
cellular level till next dose is received. There might be
other host factors predicting interferon response other than
pharmacokinetics of PEG interferon.
PP-142 Prevalence and risk factors for hepatitis C virus
infection in the rural area of Jilin China:
A cross-sectional population-based survey
J. Jiang1 *, Y. Pan2, Z.F. Jia1, X.M. Chi2, M.L. Wang2,
P. Zhang2. 11. Department of Clinical Epidemiology,
First Hospital of Jilin University, Changchun, China,
2Department of Hepatology, First Hospital of Jilin
University, Changchun, China
Background: Despite the fact that hepatitis C virus (HCV)
is a common infection in China, there is little information
on prevalence rates, particularly in the rural area of Jilin
province. Blood transfusions and more intravenous drug used
are risk factors of spreading the virus. In order to investigate
HCV infection status and related factors associated with HCV
infections among rural people in Jilin province, a cross-
sectional population-based survey was conducted.
Methods: Blood samples from 2,849 subjects were analyzed
for Anti-HCV, hematological, blood chemistry and HCV-RNA
tests. A standardized questionnaire concerning the socio-
demographic characteristics and potential risk factors was
carried out.
Results: The HCV infection was detected in 33.2%
(947/2849) of subjects at this survey. HCV RNA were
detected in 873 HCV-infected individuals, 18.8% (164) of
HCV-infected individuals has a spontaneous clearance of
virus infection. 57.7% (409/709) of HCV-infected individuals
were detected to have high-levels of the viral load (>400000
IU/ml). HCV genotypes of 252 samples were examined,
142 (56.3%) individuals had the infection of subtype 1b;
101 (40.1%) had subtype 2a; 9 (3.6%) had a co-infection
of subtype 1b/2a. Multivariate analyses revealed that risk
factors related to HCV infection were unsafe injections (OR:
11.7; 95%CI: 5.6 24.2), caffeine-sodium benzoate injections
(OR: 7.1; 95%CI: 4.4 11.3), age (40years, OR: 5.8; 95%CI:
3.9 8.1) and sex (in male, OR: 1.8; 95%CI: 1.5 2.2).
Conclusion: The most common source of HCV spreading
was a caffeine-sodium benzoate injection. Subtype 1b and
2a are predominant HCV genotypes in the area of Jilin
province. Public health measures should be taken to reduce
the abuse of intravenous injections and exposure of unsafe
injections.
PP-143 Hepatitis C virus genotype and subtype
distribution in China
W. Ju1 *, S. Yang1, Q. Wang1, H.C. Xing1, W. Xie1, Y. Xie1,
J. Cheng1. 1Beijing Ditan Hospital, Capital Medical
University, China
Background: Hepatitis C virus (HCV) heterogeneity accounts
for the lack of successful anti-viral therapy in some patients.
The object of this study is to determine HCV genotype and
subtype distribution in China mainland.
Methods: A total of 788 HCV RNA positive serum samples
were collected from chronic HCV infected patients from
14 geographic areas in China during 2009.10 2011.4.
Nucleotide sequence analysis of the NS5B and/or CORE-
E1 regions of the HCV genome was performed on samples.
Phylogenetic analysis was used for analysis of HCV genotype
and subtype.
Result: HCV genotype was determined in 747 samples
[94.80% (747/788)]. Genotype 1, 2, 3 and 6 were detected,
at frequencies of 73.49%, 18.88%, 4.95% and 2.68%,
respectively. No genotype 4 and 5 strains were found.
We detected subtypes 1b, 2a, 3a, 6a, 3b, 6n, and 1a
at frequencies of 73.09%, 18.88%, 3.21%, 2.14%, 1.74%,
0.54%, and 0.40%, respectively. Subtype 1b was the most
predominant [73.09% (546/747)] followed by 2a [18.88%
(141/747)].
Conclusion: This study demonstrated a genetic
heterogeneity of HCV infection in China, with at least
four HCV genotypes and seven subtypes. Clinical trials
of direct anti-HCV agents should consider this genetic
heterogeneity.
PP-144 NS5ATP9 contributes to inhibition of cell
proliferation by NS5A
Q. Wang1 *, X.S. Gao1, Y. Li2, W. Li1, Q. Yang1, J. Cheng1.
1Department of Infection Disease, Beijing Ditan Hospital,
Capital Medical University, 2Beijing Center for Physical
and Chemical Analysis, China
HCV NS5A is a remarkable protein as it clearly plays multiple
roles in mediating viral replication, host-cell interactions,
and viral pathogenesis. But on the impact of cell growth,
there were different study results. NS5ATP9, also known as
p15PAF, L5, OEACT-1, and KIAA0101, was ﬁrst identiﬁed as
a proliferating cell nuclear antigen-binding protein. Earlier
studies have shown that it might play an important role
in HCV infection. In the present study, we showed that
overexpression of NS5ATP9 inhibited the proliferation of HCC
cells, whereas knockdown of NS5ATP9 by interfering RNA
(RNAi) promoted the growth of HCC cells. Under conditions
of NS5A overexpression, RNAi targeting of NS5ATP9 could
reverse the inhibition of HCC cell proliferation by NS5A,
suggesting that NS5ATP9 could be an anti-oncogene that
plays an important role in the suppression of cell growth
mediated by HCV NS5A via MEK/ERK signal pathway.
These ﬁndings may provide new insight into the NS5A and
NS5ATP9.
PP-145 BST2/Tetherin inhibits hepatitis C virus release
from human hepatoma cells
X.B. Pan1, J.H. Chang2, T.M. Block2, J.-T. Guo2. 1Peking
University People’s Hospital, Peking University Hepatology
Institute, 2Drexel Institute for Biotechnology and Virology
Research, China
Background: Hepatitis C virus (HCV) infection is a common
cause of chronic hepatitis and is currently treated with
